Lung Cancer

Naiyer A. Rizvi, MD, discusses the utility of fam-trastuzumab deruxtecan-nxki  in non–small cell lung cancer.

Nathan A. Pennell, MD, PhD, discusses remaining challenges in non–small cell lung cancer.

Capmatinib continued to elicit a significant, durable responses in patients with metastatic non–small cell lung cancer whose tumors harbor a MET exon14 skipping mutation.

Naiyer A. Rizvi, MD, discusses treatment approaches in non–small cell lung cancer.

The RET inhibitor selpercatinib was shown to have durable efficacy with mostly low-grade adverse effects in patients with RET fusion–positive non–small-cell lung cancer.

Nathan A. Pennell, MD, PhD, discusses the evolution of targeting HER2 in lung cancer.

Leora Horn, MD, MSc, FRCPC, discusses the role of mobocertinib in patients with non​–small cell lung cancer.

Nathan Pennell, MD, PhD, discusses the evolution of targeted therapies in the field of non–small cell lung cancer.

Edward B. Garon, MD, discusses remaining questions with fam-trastuzumab deruxtecan-nxki in the field of lung cancer.

Narjust Duma, MD, discusses the importance of mitigating racial disparities in lung cancer research. 

Join us to learn more about how to navigate the new role of immunotherapy in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer on Wednesday, October 28, 2020 at 8:00 PM EDT.

Ticiana A. Leal, MD, discusses the rationale for the phase 2 ECOG-ACRIN EA5161 trial in extensive-stage small cell lung cancer.

Elaine Shum, MD, discusses emerging targeted therapies in EGFR-mutant non–small cell lung cancer.

The FDA has approved a generic form of pemetrexed for intravenous administration as a single-agent in patients with locally advanced or metastatic nonsquamous non–small cell lung cancer that has not progressed following 4 cycles of first-line platinum-based chemotherapy.

Erin Schenk, MD, PhD, discusses the rapidly evolving treatment landscape in lung cancer.

The FDA has granted a priority review designation to new drug application for tepotinib as a treatment for patient with metastatic non–small cell lung cancer whose tumors harbor a MET exon 14 skipping mutation identified via an FDA-approved test.

Joshua K. Sabari, MD, discusses novel immunotherapy combinations that are under investigation in non–small cell lung cancer.

Experts share insight on their clinical experience with interstitial lung disease.

Recently developed treatments for HER2-positive breast cancer, lung cancers, and gastrointestinal cancers include antibody-drug conjugates, CDK4/6 inhibitors, and immuno-oncology agents.

Edward B. Garon, MD, discusses the expanding treatment landscape in lung cancer.

In our exclusive interview, Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.